Institut Pasteur Korea
Institut Pasteur Korea is a nonprofit research institute dedicated to public health, focusing on infectious diseases such as COVID-19, tuberculosis, antibiotic resistance, viral hepatitis, cancer, and neglected diseases. It aims to uncover physiological and pathological processes to develop new strategies for diagnosis, prevention, and treatment, and collaborates internationally as part of the Pasteur Network.
Industries
Nr. of Employees
medium (51-250)
Patents
Pharmaceutical composition for preventing or treating coronavirus disease-19
US-12544360-B2
View Details2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors
US-11447486-B2
View Details
Pharmaceutical composition for preventing or treating coronavirus disease-19
US-12544360-B2
View Details2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors
US-11447486-B2
View DetailsServices
On-site open-lab access and shared infrastructure for virus research projects, available to industry, academia and research institutes.
Fee-for-service screening of compound libraries, assay development and data generation using HTS/HCS platforms.
Workshops and courses on high-content screening and therapeutics discovery methods aimed at researchers and technical staff.
Project-based support for designing and implementing bio-core facilities and research infrastructure.
On-site open-lab access and shared infrastructure for virus research projects, available to industry, academia and research institutes.
Fee-for-service screening of compound libraries, assay development and data generation using HTS/HCS platforms.
Workshops and courses on high-content screening and therapeutics discovery methods aimed at researchers and technical staff.
Project-based support for designing and implementing bio-core facilities and research infrastructure.
Expertise Areas
- Infectious disease research
- Drug discovery and small-molecule screening
- Translational research and clinical development
- High-throughput and high-content screening
Key Technologies
- High-throughput screening (HTS)
- High-content screening (HCS)
- Small-molecule library screening
- Assay development for antibacterial and antiviral discovery
News & Updates
Open Lab facility for industry, academia, and research institute - Virus Research Resource Center (RRC)
Excellent phase 2A results of Q203 * (Telacebec) presented at WHO conference and published in AJRCCM
Excellent phase 2A results of Q203 * (Telacebec) presented at WHO conference and published in AJRCCM
High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae
Open Lab facility for industry, academia, and research institute - Virus Research Resource Center (RRC)
Excellent phase 2A results of Q203 * (Telacebec) presented at WHO conference and published in AJRCCM
Excellent phase 2A results of Q203 * (Telacebec) presented at WHO conference and published in AJRCCM
High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae